CU23916B1 - Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida - Google Patents

Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida

Info

Publication number
CU23916B1
CU23916B1 CU2008000006A CU20080006A CU23916B1 CU 23916 B1 CU23916 B1 CU 23916B1 CU 2008000006 A CU2008000006 A CU 2008000006A CU 20080006 A CU20080006 A CU 20080006A CU 23916 B1 CU23916 B1 CU 23916B1
Authority
CU
Cuba
Prior art keywords
methyl
imidazol
pyrimidin
trifluoro
phenyl
Prior art date
Application number
CU2008000006A
Other languages
English (en)
Other versions
CU20080006A7 (es
Inventor
Paul Manley
Wen-Chung Shieh
Paul Sutton
Piotr Karpinski
Raeann Wu
Stéphanie Monnier
Jörg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23916(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20080006A7 publication Critical patent/CU20080006A7/es
Publication of CU23916B1 publication Critical patent/CU23916B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se preparan formas cristalinas de la base libre de 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida y sales de la misma mediante diferentes procesos.
CU2008000006A 2005-07-20 2008-01-17 Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida CU23916B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
PCT/US2006/027875 WO2007015870A2 (en) 2005-07-20 2006-07-18 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (2)

Publication Number Publication Date
CU20080006A7 CU20080006A7 (es) 2011-02-24
CU23916B1 true CU23916B1 (es) 2013-07-31

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2008000006A CU23916B1 (es) 2005-07-20 2008-01-17 Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida

Country Status (42)

Country Link
US (4) US8343984B2 (es)
EP (5) EP1912973B1 (es)
JP (3) JP5289948B2 (es)
KR (3) KR20130085444A (es)
CN (2) CN103804356A (es)
AR (1) AR054846A1 (es)
AU (3) AU2006276204A1 (es)
BR (1) BRPI0613615B1 (es)
CA (1) CA2614334C (es)
CR (1) CR9657A (es)
CU (1) CU23916B1 (es)
CY (2) CY1113076T1 (es)
DK (2) DK1912973T3 (es)
EA (2) EA016856B1 (es)
EC (1) ECSP088119A (es)
ES (3) ES2648288T3 (es)
GE (1) GEP20115302B (es)
GT (1) GT200600315A (es)
HN (1) HN2008000311A (es)
HR (2) HRP20120573T1 (es)
HU (1) HUE031791T2 (es)
IL (2) IL188189A0 (es)
JO (1) JO3308B1 (es)
LT (1) LT2284167T (es)
MA (1) MA29626B1 (es)
MX (1) MX2008000899A (es)
MY (1) MY148554A (es)
NI (1) NI200800017A (es)
NO (1) NO341930B1 (es)
NZ (1) NZ564409A (es)
PE (1) PE20070214A1 (es)
PH (1) PH12013501590A1 (es)
PL (2) PL2284167T5 (es)
PT (2) PT1912973E (es)
RS (1) RS55929B2 (es)
SG (1) SG163620A1 (es)
SI (2) SI2284167T2 (es)
SM (1) SMP200800011B (es)
TN (1) TNSN08029A1 (es)
TW (1) TWI406661B (es)
UA (1) UA94234C2 (es)
WO (1) WO2007015870A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
JP2009532438A (ja) * 2006-04-07 2009-09-10 ノバルティス アクチエンゲゼルシャフト 白血病の処置のためのピリミジルアミノベンズアミド化合物との組合せでのｃ−Ｓｒｃ阻害剤の使用
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
PL2240172T3 (pl) * 2007-12-21 2014-08-29 Novartis Ag Kombinacja nilotynibu i chlorambucylu do leczenia przewlekłej białaczki limfocytowej
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
CN102203084B (zh) 2008-11-05 2014-10-29 特瓦制药工业有限公司 盐酸尼洛替尼晶型
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
MX2011009310A (es) 2009-03-06 2011-10-13 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de trastornos mediados por la cinasa que contiene un motivo de cierre de leucina y alfa esteril (zak).
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
KR101853596B1 (ko) 2009-10-23 2018-04-30 노파르티스 아게 Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (es) * 2010-01-15 2016-09-02
EP2558098A2 (en) 2010-04-16 2013-02-20 Novartis AG Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
KR20130042498A (ko) * 2010-06-21 2013-04-26 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 염 및 이의 결정형
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (en) * 2010-11-26 2012-05-31 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN103889422A (zh) 2011-10-28 2014-06-25 诺华股份有限公司 治疗胃肠道间质瘤的方法
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2779995A1 (en) 2011-11-14 2014-09-24 Novartis AG Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
CN104427986A (zh) 2012-07-11 2015-03-18 诺华股份有限公司 治疗胃肠道基质瘤的方法
EP2906554A4 (en) * 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
EP2909191B1 (en) * 2012-10-19 2019-03-20 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
HK1211032A1 (en) * 2013-02-21 2016-05-13 辉瑞大药厂 Solid forms of a selective cdk4/6 inhibitor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
BR112015026827A2 (pt) * 2013-04-24 2017-09-05 Dr Reddy´S Laboratories Ltd Formas polimórficas de cloridrato de nilotinibe
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
WO2016058081A1 (en) * 2014-10-16 2016-04-21 Apotex Inc. Solid forms of nilotinib hydrochloride
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
DK3430004T3 (da) 2016-03-14 2020-09-28 Pliva Hrvatska D O O Faststofformer af nilotinibsalte
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
CA3193829A1 (en) 2020-09-29 2022-04-07 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Pharmaceuticals Gmbh Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
CN113788817A (zh) * 2021-09-27 2021-12-14 南京海润医药有限公司 一种尼罗替尼半盐酸盐一水合物晶型及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CN102274230B (zh) * 2003-11-18 2015-07-01 诺华股份有限公司 Kit突变形式的抑制剂
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
EP2543665A2 (en) 2013-01-09
HK1116783A1 (en) 2009-01-02
AU2012201453B2 (en) 2013-09-05
EP2284167B1 (en) 2017-02-01
KR20130085444A (ko) 2013-07-29
PE20070214A1 (es) 2007-04-02
PL2284167T3 (pl) 2017-07-31
DK1912973T3 (da) 2012-07-23
PT1912973E (pt) 2012-09-03
ES2386974T3 (es) 2012-09-10
HRP20170634T4 (hr) 2020-02-07
US20130165465A1 (en) 2013-06-27
SMAP200800011A (it) 2008-02-27
SI2284167T1 (sl) 2017-05-31
SI2284167T2 (sl) 2020-03-31
HN2008000311A (es) 2011-01-24
AR054846A1 (es) 2007-07-18
NO20080820L (no) 2008-04-15
US20080269269A1 (en) 2008-10-30
SI1912973T1 (sl) 2012-08-31
EP2284167B2 (en) 2019-11-27
EA200800201A1 (ru) 2008-06-30
CY1119624T1 (el) 2018-04-04
PT2284167T (pt) 2017-05-15
US8343984B2 (en) 2013-01-01
JP5798101B2 (ja) 2015-10-21
US20130023548A1 (en) 2013-01-24
ECSP088119A (es) 2008-02-20
GT200600315A (es) 2007-03-19
IL188189A0 (en) 2008-03-20
CY1113076T1 (el) 2016-04-13
EP2284167A3 (en) 2011-03-02
JP2013018789A (ja) 2013-01-31
KR20080027853A (ko) 2008-03-28
AU2011202047A1 (en) 2011-05-26
CN102358736A (zh) 2012-02-22
CA2614334C (en) 2015-04-21
SMP200800011B (it) 2008-02-27
AU2012201453A1 (en) 2012-04-05
EP2284168A3 (en) 2011-04-13
US8415363B2 (en) 2013-04-09
EA016856B1 (ru) 2012-08-30
TW200740793A (en) 2007-11-01
NI200800017A (es) 2009-03-03
MY148554A (en) 2013-04-30
IL214659A0 (en) 2011-09-27
SG163620A1 (en) 2010-08-30
JP5289948B2 (ja) 2013-09-11
HUE031791T2 (en) 2017-08-28
CA2614334A1 (en) 2007-02-08
MX2008000899A (es) 2008-03-18
EA013464B1 (ru) 2010-04-30
CU20080006A7 (es) 2011-02-24
BRPI0613615A2 (pt) 2011-01-18
JO3308B1 (ar) 2018-09-16
EP2284168A2 (en) 2011-02-16
EP2543665A3 (en) 2013-05-29
EP1912973A2 (en) 2008-04-23
DK2284167T4 (da) 2020-03-02
NO341930B1 (no) 2018-02-19
HRP20170634T1 (hr) 2017-06-30
EA201000145A1 (ru) 2010-06-30
DK2284167T3 (en) 2017-05-01
GEP20115302B (en) 2011-10-10
ES2623608T5 (es) 2020-06-18
US8829015B2 (en) 2014-09-09
RS55929B2 (sr) 2020-12-31
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
EP2535337B1 (en) 2017-08-23
TWI406661B (zh) 2013-09-01
LT2284167T (lt) 2017-04-25
BRPI0613615B1 (pt) 2022-02-08
MA29626B1 (fr) 2008-07-01
KR101651288B1 (ko) 2016-08-25
KR20130077915A (ko) 2013-07-09
US20140343087A1 (en) 2014-11-20
JP2014221831A (ja) 2014-11-27
PL2284167T5 (pl) 2020-07-27
TNSN08029A1 (en) 2009-07-14
AU2006276204A1 (en) 2007-02-08
ES2648288T3 (es) 2017-12-29
JP2009502795A (ja) 2009-01-29
WO2007015870A3 (en) 2007-06-07
PL1912973T3 (pl) 2012-09-28
CR9657A (es) 2008-04-16
PH12013501590A1 (en) 2015-09-21
ES2623608T3 (es) 2017-07-11
WO2007015870A2 (en) 2007-02-08
EP2284167A2 (en) 2011-02-16
EP1912973B1 (en) 2012-06-13
HRP20120573T1 (hr) 2012-08-31
UA94234C2 (uk) 2011-04-26
RS55929B1 (sr) 2017-09-29
EP2535337A1 (en) 2012-12-19
NZ564409A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CU23916B1 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
ECSP088118A (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
UY3493Q (es) Esponja
PL1636190T3 (pl) Trwały kryształ związku 4-oksochinoliny
EA200700537A1 (ru) Триазолофталазины
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
DE602005018653D1 (de) Aktive auswahl der bestätigungsquelle
ATE509933T1 (de) Pentacyclische kinaseinhibitoren
CU20120123A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
EA200701626A1 (ru) Новые 6-пиридилфенантридины
RU2004132147A (ru) Адаптоген
FI20040178A0 (fi) Monitelakalanteri
UY3516Q (es) Inhalador-rotahaler-m
RU2008127281A (ru) Производные нетропсина, обладающие антивирусной активностью
UY29682A1 (es) Formas cristalinas de 4-metil-n-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
FR2892698B1 (fr) Quille active
ES1058748Y (es) Calendario.
UA3387U (uk) Застосування 2-феніл-3-карбетокси-4-диметиламінометил-5-оксибензофурану гідрохлориду (вінборону) як утеролітичного засобу
ES1057560Y (es) Mesa-atril abatible y desmontable.
UY3515Q (es) Parte superior inhalador-rotahaler-m-top
ES1059591Y (es) Mesa multiformas.
ES1060048Y (es) Agenda

Legal Events

Date Code Title Description
FG Grant of patent